143 related articles for article (PubMed ID: 28670882)
1. Circulating Hypermethylated RASSF1A as a Molecular Biomarker for Diagnosis of Hepatocellular Carcinoma.
Mansour LA; El Raziky M; Mohamed AA; Mahmoud EH; Hamdy S; El Sayed EH
Asian Pac J Cancer Prev; 2017 Jun; 18(6):1637-1643. PubMed ID: 28670882
[TBL] [Abstract][Full Text] [Related]
2. Methylation of tumour suppressor genes
El-Bendary M; Nour D; Arafa M; Neamatallah M
Br J Biomed Sci; 2020 Jan; 77(1):35-40. PubMed ID: 31790342
[No Abstract] [Full Text] [Related]
3. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma.
Chan KC; Lai PB; Mok TS; Chan HL; Ding C; Yeung SW; Lo YM
Clin Chem; 2008 Sep; 54(9):1528-36. PubMed ID: 18653827
[TBL] [Abstract][Full Text] [Related]
4. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C?
Mohamed NA; Swify EM; Amin NF; Soliman MM; Tag-Eldin LM; Elsherbiny NM
Arab J Gastroenterol; 2012 Sep; 13(3):111-5. PubMed ID: 23122451
[TBL] [Abstract][Full Text] [Related]
5. Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection.
Dong X; He H; Zhang W; Yu D; Wang X; Chen Y
Diagn Pathol; 2015 Aug; 10():133. PubMed ID: 26238200
[TBL] [Abstract][Full Text] [Related]
6. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma.
Schagdarsurengin U; Wilkens L; Steinemann D; Flemming P; Kreipe HH; Pfeifer GP; Schlegelberger B; Dammann R
Oncogene; 2003 Mar; 22(12):1866-71. PubMed ID: 12660822
[TBL] [Abstract][Full Text] [Related]
7. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA.
Zhang YJ; Wu HC; Shen J; Ahsan H; Tsai WY; Yang HI; Wang LY; Chen SY; Chen CJ; Santella RM
Clin Cancer Res; 2007 Apr; 13(8):2378-84. PubMed ID: 17438096
[TBL] [Abstract][Full Text] [Related]
8. Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma.
Xu G; Zhou X; Xing J; Xiao Y; Jin B; Sun L; Yang H; Du S; Xu H; Mao Y
Cancer Cell Int; 2020 Nov; 20(1):547. PubMed ID: 33292241
[TBL] [Abstract][Full Text] [Related]
9. Ras Association Domain Family 1A Gene Promoter Methylation as a Biomarker for Chronic Viral Hepatitis C-related Hepatocellular Carcinoma.
Abou Zeid AA; El-Sayed ET; Ahdy JK; Tawfik MR
Cureus; 2023 Sep; 15(9):e45687. PubMed ID: 37868533
[TBL] [Abstract][Full Text] [Related]
10. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
11. RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian Patients.
Araújo OC; Rosa AS; Fernandes A; Niel C; Villela-Nogueira CA; Pannain V; Araujo NM
PLoS One; 2016; 11(4):e0153796. PubMed ID: 27078152
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications.
Xu B; Di J; Wang Z; Han X; Li Z; Luo X; Zheng Q
Biochem Biophys Res Commun; 2013 Aug; 438(2):324-8. PubMed ID: 23891693
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of DNMT1 mediated by HBx suppresses RASSF1A expression independent of DNA methylation.
Qiu X; Zhang L; Lu S; Song Y; Lao Y; Hu J; Fan H
Oncol Rep; 2014 Jan; 31(1):202-8. PubMed ID: 24247422
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
15. Circulating miRNA-122, miRNA-199a, and miRNA-16 as Biomarkers for Early Detection of Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C Virus Infection.
El-Abd NE; Fawzy NA; El-Sheikh SM; Soliman ME
Mol Diagn Ther; 2015 Aug; 19(4):213-20. PubMed ID: 26133725
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma.
Hu L; Chen G; Yu H; Qiu X
Hepatol Int; 2010 Jan; 4(1):423-32. PubMed ID: 20305761
[TBL] [Abstract][Full Text] [Related]
17. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma.
Yeo W; Wong N; Wong WL; Lai PB; Zhong S; Johnson PJ
Liver Int; 2005 Apr; 25(2):266-72. PubMed ID: 15780049
[TBL] [Abstract][Full Text] [Related]
18. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma.
Saelee P; Wongkham S; Chariyalertsak S; Petmitr S; Chuensumran U
Asian Pac J Cancer Prev; 2010; 11(6):1677-81. PubMed ID: 21338215
[TBL] [Abstract][Full Text] [Related]
19. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
